Sumitomo Mitsui Trust Holdings, Inc. Syros Pharmaceuticals, Inc. Transaction History

Sumitomo Mitsui Trust Holdings, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 02, 2021	SELL	$5.01 - $7.48 $25.9 Million - $38.6 Million	-5,166,290 Closed	0 $0
Q1 2021 Apr 30, 2021	BUY	$7.19 - $14.95 $5.64 Million - $11.7 Million	784,298 Added 17.9%	5,166,290 $38.6 Million
Q4 2020 Feb 05, 2021	BUY	$6.66 - $14.66 $1.33 Million - $2.93 Million	199,646 Added 4.77%	4,381,992 $47.5 Million
Q3 2020 Oct 30, 2020	SELL	$8.69 - $14.47 $4.71 Million - $7.85 Million	-542,428 Reduced 11.48%	4,182,346 $37 Million
Q2 2020 Jul 27, 2020	SELL	$5.21 - $11.03 $1.04 Million - $2.21 Million	-200,432 Reduced 4.07%	4,724,774 $50.4 Million
Q1 2020 Apr 27, 2020	SELL	$4.46 - $9.2 $220,573 - $454,995	-49,456 Reduced 0.99%	4,925,206 $29.2 Million
Q4 2019 Jan 31, 2020	BUY	$4.52 - $10.1 $1.54 Million - $3.44 Million	340,889 Added 7.36%	4,974,662 $34.4 Million
Q3 2019 Oct 31, 2019	BUY	$7.14 - $11.65 $21.7 Million - $35.5 Million	3,044,728 Added 191.61%	4,633,773 $48.1 Million
Q2 2019 Jul 29, 2019	BUY	$5.5 - $9.75 $4.98 Million - $8.82 Million	904,570 Added 132.16%	1,589,045 $14.7 Million
Q1 2019 May 08, 2019	BUY	$5.51 - $9.59 $3.77 Million - $6.56 Million	684,475 New	684,475 $6.26 Million

Ticker SYRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,236,200
Market Cap $43.1M
Description
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically def...

Get notified when there are updates to the investment portfolio of Sumitomo Mitsui Trust Holdings, Inc., based on Form 13F filings with the SEC.

Stay updated on Sumitomo Mitsui Trust Holdings, Inc. with notifications on news.